# Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma

> **NCT06485947** · PHASE1 · RECRUITING · sponsor: **Princess Maxima Center for Pediatric Oncology** · enrollment: 38 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **BIOLOGICAL:** Dinutuximab beta
- **DRUG:** chemotherapy treatment called GPOH
- **DRUG:** chemotherapy treatment called rapid COJEC

## Key facts

- **NCT ID:** NCT06485947
- **Lead sponsor:** Princess Maxima Center for Pediatric Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-28
- **Primary completion:** 2030-07-01
- **Final completion:** 2031-12-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06485947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06485947, "Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06485947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*